FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899740934> ?p ?o ?g. }

• W2899740934 abstract "Adherence is critical for successful topical, vaginally delivered anti-retroviral (ARV)-based HIV pre-exposure prophylaxis (PrEP). Quantitating systemic or tissue ARV levels through LC-MS/MS is currently viewed as the most reliable measure of adherence. However, for placebo-controlled trials, this is a high cost analysis that measures adherence only in the drug treatment group. A desirable marker of adherence is one that is measured in both placebo and drug treatment groups using a simple on-site clinical laboratory test, which allows necessary interventions for supporting participant adherence. Our objective was to develop adherence markers for four vaginal placebo products currently used as microbicide delivery systems: gel, film, insert, and intravaginal ring. Excipient and spectroscopy-based approaches were used for preclinical development of the placebo markers and subsequently validated by the CONRAD 135 study. The study collected vaginal swabs collected each day for 1 week post vaginal application of gel, film, or insert in the clinic with or without sex. Intravaginal rings were collected after 1 day, 7, and 30 days of use.Placebo gel, film, and insert in vaginal swabs were successfully detected by specific excipient colorimetric or probe-based assays for hydroxyethylcellulose, glycerin, and sorbitol respectively, as well as spectroscopy-based prediction models. The range of detection for gel, film, and insert in swabs collected up to 16 h post vaginal application was 70-100% of the total swabs per time point, with some markers showing potential for longer duration. Decreasing residual glycerin levels and increasing bioanalyte penetration of vaginally used intravaginal rings showed significant changes between 1 and 30 days of use.We demonstrated clinical proof-of-concept that adherence markers for placebo product can be measured using simple, lower cost approaches. Measuring adherence in both placebo and drug arms of a HIV PrEP study would better inform future trial designs." @default.
• W2899740934 created "2018-11-16" @default.
• W2899740934 creator A5002553105 @default.
• W2899740934 creator A5024613253 @default.
• W2899740934 creator A5031286794 @default.
• W2899740934 creator A5032897934 @default.
• W2899740934 creator A5048400225 @default.
• W2899740934 creator A5056607544 @default.
• W2899740934 creator A5076589614 @default.
• W2899740934 creator A5087235619 @default.
• W2899740934 creator A5088429100 @default.
• W2899740934 date "2018-11-07" @default.
• W2899740934 modified "2023-09-30" @default.
• W2899740934 title "Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies" @default.
• W2899740934 cites W1827376131 @default.
• W2899740934 cites W1970786548 @default.
• W2899740934 cites W1979495409 @default.
• W2899740934 cites W1981599075 @default.
• W2899740934 cites W1987467897 @default.
• W2899740934 cites W1988491543 @default.
• W2899740934 cites W2014003991 @default.
• W2899740934 cites W2022571376 @default.
• W2899740934 cites W2023061269 @default.
• W2899740934 cites W2027373982 @default.
• W2899740934 cites W2029280470 @default.
• W2899740934 cites W2031585206 @default.
• W2899740934 cites W2044369525 @default.
• W2899740934 cites W2047175099 @default.
• W2899740934 cites W2089822628 @default.
• W2899740934 cites W2103920597 @default.
• W2899740934 cites W2108393429 @default.
• W2899740934 cites W2120144944 @default.
• W2899740934 cites W2138170968 @default.
• W2899740934 cites W2146634980 @default.
• W2899740934 cites W2147982456 @default.
• W2899740934 cites W2168251450 @default.
• W2899740934 cites W2169840816 @default.
• W2899740934 cites W2290010664 @default.
• W2899740934 cites W2409495306 @default.
• W2899740934 cites W2464724361 @default.
• W2899740934 cites W2558446330 @default.
• W2899740934 cites W2608814213 @default.
• W2899740934 cites W2767462021 @default.
• W2899740934 cites W2803481332 @default.
• W2899740934 doi "https://doi.org/10.1186/s40169-018-0213-6" @default.
• W2899740934 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6219998" @default.
• W2899740934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30402770" @default.
• W2899740934 hasPublicationYear "2018" @default.
• W2899740934 type Work @default.
• W2899740934 sameAs 2899740934 @default.
• W2899740934 citedByCount "6" @default.
• W2899740934 countsByYear W28997409342019 @default.
• W2899740934 countsByYear W28997409342020 @default.
• W2899740934 countsByYear W28997409342021 @default.
• W2899740934 countsByYear W28997409342022 @default.
• W2899740934 countsByYear W28997409342023 @default.
• W2899740934 crossrefType "journal-article" @default.
• W2899740934 hasAuthorship W2899740934A5002553105 @default.
• W2899740934 hasAuthorship W2899740934A5024613253 @default.
• W2899740934 hasAuthorship W2899740934A5031286794 @default.
• W2899740934 hasAuthorship W2899740934A5032897934 @default.
• W2899740934 hasAuthorship W2899740934A5048400225 @default.
• W2899740934 hasAuthorship W2899740934A5056607544 @default.
• W2899740934 hasAuthorship W2899740934A5076589614 @default.
• W2899740934 hasAuthorship W2899740934A5087235619 @default.
• W2899740934 hasAuthorship W2899740934A5088429100 @default.
• W2899740934 hasBestOaLocation W28997409341 @default.
• W2899740934 hasConcept C117214928 @default.
• W2899740934 hasConcept C126322002 @default.
• W2899740934 hasConcept C142724271 @default.
• W2899740934 hasConcept C197746943 @default.
• W2899740934 hasConcept C203014093 @default.
• W2899740934 hasConcept C204787440 @default.
• W2899740934 hasConcept C27081682 @default.
• W2899740934 hasConcept C2908647359 @default.
• W2899740934 hasConcept C2986740045 @default.
• W2899740934 hasConcept C3013748606 @default.
• W2899740934 hasConcept C71924100 @default.
• W2899740934 hasConcept C99454951 @default.
• W2899740934 hasConceptScore W2899740934C117214928 @default.
• W2899740934 hasConceptScore W2899740934C126322002 @default.
• W2899740934 hasConceptScore W2899740934C142724271 @default.
• W2899740934 hasConceptScore W2899740934C197746943 @default.
• W2899740934 hasConceptScore W2899740934C203014093 @default.
• W2899740934 hasConceptScore W2899740934C204787440 @default.
• W2899740934 hasConceptScore W2899740934C27081682 @default.
• W2899740934 hasConceptScore W2899740934C2908647359 @default.
• W2899740934 hasConceptScore W2899740934C2986740045 @default.
• W2899740934 hasConceptScore W2899740934C3013748606 @default.
• W2899740934 hasConceptScore W2899740934C71924100 @default.
• W2899740934 hasConceptScore W2899740934C99454951 @default.
• W2899740934 hasFunder F4320306115 @default.
• W2899740934 hasFunder F4320306137 @default.
• W2899740934 hasFunder F4320310979 @default.
• W2899740934 hasFunder F4320314694 @default.
• W2899740934 hasIssue "1" @default.
• W2899740934 hasLocation W28997409341 @default.
• W2899740934 hasLocation W28997409342 @default.
• W2899740934 hasLocation W28997409343 @default.
• W2899740934 hasLocation W28997409344 @default.

• next